CY1114171T1 - Συζευγματα αλλεργιογονων γατας και χρησεις τους - Google Patents

Συζευγματα αλλεργιογονων γατας και χρησεις τους

Info

Publication number
CY1114171T1
CY1114171T1 CY20131100638T CY131100638T CY1114171T1 CY 1114171 T1 CY1114171 T1 CY 1114171T1 CY 20131100638 T CY20131100638 T CY 20131100638T CY 131100638 T CY131100638 T CY 131100638T CY 1114171 T1 CY1114171 T1 CY 1114171T1
Authority
CY
Cyprus
Prior art keywords
cat
antigen
compositions
vlp
conjunctions
Prior art date
Application number
CY20131100638T
Other languages
English (en)
Inventor
Martin Bachmann
Monika Bauer
Klaus Dietmeier
Nicole Schmitz
Stephan Utzinger
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of CY1114171T1 publication Critical patent/CY1114171T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση είναι στο πεδίο της ιατρικής, της δημόσιας υγείας, της ανοσολογίας, της μοριακής βιολογίας και της ιολογίας. Η εφεύρεση παρέχει συνθέσεις οι οποίες περιλαμβάνουν ένα ιόμορφο σωματίδιο (VLΡ) ή ένα σωμάτιο ιού και τουλάχιστον ένα αντιγόνο, ειδικότερα τουλάχιστον ένα αντιγόνο γάτας, και πιο συγκεκριμένα τουλάχιστον ένα αντιγόνο γάτας το οποίο είναι ένα ανθρώπινο αλλεργιογόνο. Σε ορισμένες υλοποιήσεις, το αντιγόνο είναι ένα Fel d1 αντιγόνο ή ένα θραύσμα αυτού, ομοιοπολικά συνδεδεμένο με το VLP. Η εφεύρεση επίσης παρέχει μεθόδους για παρασκευή των συνθέσεων. Οι συνθέσεις της εφεύρεσης επάγουν αποτελεσματικές άνοσες αποκρίσεις, ειδικότερα αποκρίσεις αντισωμάτων, σε θηλαστικά, ειδικότερα ανθρώπους. Οι συνθέσεις και μέθοδοι της εφεύρεσης είναι χρήσιμες στην παραγωγή εμβολίων, ειδικότερα για την αντιμετώπιση και/ή πρόληψη αλλεργιών σε πιτυρίδα γάτας και άλλα αντιγόνα και αλλεργιογόνα γάτας.
CY20131100638T 2005-03-18 2013-07-26 Συζευγματα αλλεργιογονων γατας και χρησεις τους CY1114171T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66291805P 2005-03-18 2005-03-18
EP06725140.5A EP1868642B1 (en) 2005-03-18 2006-03-17 Cat allergen fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
CY1114171T1 true CY1114171T1 (el) 2016-08-31

Family

ID=36843236

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100638T CY1114171T1 (el) 2005-03-18 2013-07-26 Συζευγματα αλλεργιογονων γατας και χρησεις τους

Country Status (19)

Country Link
US (3) US7767212B2 (el)
EP (1) EP1868642B1 (el)
JP (2) JP5302671B2 (el)
KR (1) KR20070112225A (el)
CN (2) CN103203016A (el)
AU (1) AU2006224529B2 (el)
BR (1) BRPI0608455A2 (el)
CA (1) CA2599218C (el)
CY (1) CY1114171T1 (el)
DK (1) DK1868642T3 (el)
ES (1) ES2424229T3 (el)
IL (1) IL185103A0 (el)
MX (1) MX2007011160A (el)
NZ (1) NZ561040A (el)
PL (1) PL1868642T3 (el)
PT (1) PT1868642E (el)
RU (1) RU2414239C2 (el)
WO (1) WO2006097530A2 (el)
ZA (1) ZA200707413B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
EP2338510A1 (en) * 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas
US20070184068A1 (en) * 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007113633A2 (en) * 2006-04-03 2007-10-11 Pfizer Products Inc. Immunogenic compositions comprising cat allergen fel dl
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
PL2032592T3 (pl) 2006-06-12 2013-11-29 Kuros Biosciences Ag Sposoby pakowania oligonukleotydów do cząstek wirusopodobnych z bakteriofagów RNA
DK2601969T3 (en) 2006-09-29 2016-04-18 Takeda Vaccines Inc Norovirus vaccine formulations
RU2491937C2 (ru) * 2007-07-09 2013-09-10 Нестек С.А. Способы уменьшения аллергических реакций, вызванных аллергенами окружающей среды
US9388236B2 (en) 2007-07-09 2016-07-12 Nestec Sa Methods for reducing allergies caused by environmental allergens
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
PL2324113T3 (pl) 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
BR112013011069A2 (pt) * 2009-11-05 2017-03-28 Padgett Hal geração de partículas antigênicas semelhantes a virus através de ligações de proteína-proteína
US8321012B2 (en) * 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
BR112014013035A2 (pt) 2011-12-22 2018-10-09 Hoffmann La Roche métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP2912069B1 (en) * 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3564671B1 (en) 2013-08-23 2021-09-29 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
CN105873603A (zh) 2013-12-19 2016-08-17 雀巢产品技术援助有限公司 用于减少环境中猫变应原的组合物和方法
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
EA035378B1 (ru) 2015-01-15 2020-06-04 Юниверсити Оф Копенгаген Вирусоподобная частица с эффективным экспонированием эпитопов
WO2016192788A1 (en) * 2015-06-03 2016-12-08 Universität Zürich Prorektorat Mnw Methods and compositions for preventing and treating cat or dog dander allergy
RU2018105007A (ru) 2015-09-08 2019-10-10 Университет Цюрих Композиции против аллергии на кошек
US11129882B2 (en) 2015-10-30 2021-09-28 University Of Copenhagen Virus like particle with efficient epitope display
CN105219742A (zh) * 2015-11-10 2016-01-06 海南大学 一种展示重组猫致敏原rFel d 1蛋白的免疫增强型病毒样颗粒、其表达载体及其制备与应用
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
FR3054547B1 (fr) * 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
US20220073946A1 (en) 2018-12-20 2022-03-10 Saiba AG Virus-like particles of cmv modified by fusion
WO2023176206A1 (ja) * 2022-03-18 2023-09-21 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
CN114933639B (zh) * 2022-05-05 2023-12-29 中国农业科学院兰州兽医研究所 非洲猪瘟病毒p72N抗原表位蛋白及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163778A (en) * 1978-05-04 1979-08-07 The Foundation for the Study of Asthma and Related Diseases Asthma immunotherapy
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
EP0420913B1 (en) 1988-06-14 1995-11-15 Cell Med, Inc. Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same
US6120769A (en) 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
GB9213601D0 (en) 1992-06-26 1992-08-12 Mastico Robert A Protein based delivery system
JPH10505356A (ja) 1994-09-02 1998-05-26 イミユロジク・フアーマシユーチカル・コーポレーシヨン ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
US6759234B1 (en) 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
EP1037663A2 (en) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
RU2245163C2 (ru) * 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
TR200503031T2 (tr) 1999-09-25 2005-09-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
EP1278542A2 (en) * 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
MXPA03004174A (es) 2000-11-16 2004-12-02 Alk Abello As Alergenos mutantes novedosos.
EP1219300B1 (en) 2000-12-28 2006-12-06 BIOMAY Produktions- und Handels- Aktiengesellschaft Treatment of allergies
EP1221317A1 (en) 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
CA2441476A1 (en) 2001-03-02 2002-09-12 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
BR0213950A (pt) * 2001-11-07 2004-08-24 Cytos Biotechnology Ag Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
CA2465981A1 (en) * 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays comprising rankl for treatment of bone disease
RU2324704C2 (ru) * 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Молекулярные массивы антигенов
WO2004009124A2 (en) 2002-07-19 2004-01-29 Cytos Biotechnology Ag Ghrelin-carrier conjugates
EP1530585A2 (en) 2002-08-22 2005-05-18 Cytos Biotechnology AG Inducible alphaviral/orip based gene expression system
CA2503886A1 (en) 2002-11-01 2004-05-13 Alk-Abello A/S Recombinant protein variants
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1605973B1 (en) * 2003-03-26 2012-09-26 Cytos Biotechnology AG Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
US20090117136A1 (en) * 2003-04-24 2009-05-07 Imvision Gmbh Recombinant allergen
WO2005004907A1 (en) * 2003-07-10 2005-01-20 Cytos Biotechnology Ag Packaged virus-like particles
ES2424229T3 (es) * 2005-03-18 2013-09-30 Cytos Biotechnology Ag Proteínas de fusión de alérgenos de gato y utilización de las mismas

Also Published As

Publication number Publication date
WO2006097530A2 (en) 2006-09-21
CN103203016A (zh) 2013-07-17
PT1868642E (pt) 2013-07-10
RU2007138265A (ru) 2009-04-27
CN101141979A (zh) 2008-03-12
PL1868642T3 (pl) 2013-10-31
IL185103A0 (en) 2007-12-03
RU2414239C2 (ru) 2011-03-20
US20090175896A1 (en) 2009-07-09
JP2013155176A (ja) 2013-08-15
JP2008535800A (ja) 2008-09-04
US20110045013A1 (en) 2011-02-24
US20130344098A1 (en) 2013-12-26
WO2006097530A3 (en) 2007-06-21
CA2599218A1 (en) 2006-09-21
AU2006224529B2 (en) 2012-05-24
EP1868642A2 (en) 2007-12-26
US7767212B2 (en) 2010-08-03
BRPI0608455A2 (pt) 2010-01-05
EP1868642B1 (en) 2013-05-08
ES2424229T3 (es) 2013-09-30
KR20070112225A (ko) 2007-11-22
CA2599218C (en) 2015-08-11
DK1868642T3 (da) 2013-06-24
ZA200707413B (en) 2009-01-28
CN101141979B (zh) 2013-05-08
AU2006224529A1 (en) 2006-09-21
NZ561040A (en) 2009-04-30
MX2007011160A (es) 2007-11-13
JP5302671B2 (ja) 2013-10-02

Similar Documents

Publication Publication Date Title
CY1114171T1 (el) Συζευγματα αλλεργιογονων γατας και χρησεις τους
CY1120096T1 (el) Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
DE60329106D1 (de) Ghrelin-träger-konjugate
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
BR0206565A (pt) Arranjo de antìgeno molecular
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
El Bissati et al. Protein nanovaccine confers robust immunity against Toxoplasma
ATE506964T1 (de) Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
NO20054608L (no) Influensavirusvaksine
DE60335186D1 (de) Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
CY1110585T1 (el) ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ
WO2006063974A3 (en) Il-15 antigen arrays and uses thereof
BR0213950A (pt) Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
DK1441764T3 (da) Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom
CY1109036T1 (el) Εμβολιο περιλαμβανον εναν εξασθενημενο ιο πανωλης
WO2009080823A3 (en) Nerve growth factor conjugates and uses thereof
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
DE602005026688D1 (de) Toleranzstudienverfahren bei mhc-ii-transgenen tieren
WO2003059386A3 (en) Prion protein carrier-conjugates
JPWO2009057763A1 (ja) 新規アジュバント
Plebanski et al. Nanotechnology and vaccine development: methods to study and manipulate the interaction of nanoparticles with the immune system
Sautto et al. New insights for immune-based diagnosis and therapy for infectious diseases
Sichangi Understanding Mechanisms of Actions for Vaccine Adjuvants Critical for Designing Effective Vaccines: A narrative review
CY1116497T1 (el) Λειτουργικα ιομορφα σωματιδια γριπης (vlps)
HUP0402548A2 (hu) Madárembrió-részecskékből álló biomassza vírusantigének előállítására